Anda belum login :: 14 Oct 2024 18:11 WIB
Home
|
Logon
Hidden
»
Administration
»
Collection Detail
Detail
A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, - A31, and A-33 (from Cancer Immunol Immunother 2007, 56, 1359-1366)
Bibliografi
Author:
Matsueda, Satoko
;
Yamada, Akira
;
Takao, Yukari
;
Tamura, Mayumi
;
Koumatsu, Nobukazu
;
Yutani, Shigeru
;
Ide, Tatsuya
;
Sata, Michio
;
Itoh, Kyogo
Topik:
Hepatitis
;
HCV
;
Peptide vaccine
;
CTL
;
Epitope
;
HLA-A3
;
Validation ref - 4
Bahasa:
(EN )
Penerbit:
Springer-Verlag
Tahun Terbit:
2007
Jenis:
Article - diterbitkan di jurnal ilmiah internasional
Fulltext:
art_3A10.1007_2Fs00262-007-0284-5.pdf
(445.5KB;
1 download
)
Abstract
Background Hepatitis C virus (HCV) frequently causes chronic hepatitis, cirrhosis, and hepatocellular carcinoma after long-term persistent infection. Among various genotypes of HCV, HCV1b is resistant to standard interferon therapy, and thus the development of new treatment modality is needed.
Results To provide a scientiWc basis for specific
immunotherapy for HCV1b, we investigated HCV1b-derived epitope peptides recognized by human leukocyte antigen (HLA)-A11, -A31, or -A33-restricted cytotoxic T-lymphocytes (CTLs), and report here three novel vaccine candidate peptides selected by both antibody screening and CTL-inducing capacity from among 46 peptides of conserved regions of HCV1b sequences with binding motifs to HLA-A11, -A31, and -A33. Significant levels of IgG reactive to each of the three peptides were detected in the plasma of more than 50% of the HCV1b+ patients. One peptide at positions 30–39 of the core protein induced peptide-specific CTLs from peripheral blood mononuclear cells (PBMCs) of HLA-A11+, -A31+, and -A33+ patients. The other two peptides at positions 35–43 of the core protein and at positions 918–926 of the non-structural protein 2 also induced peptide-specific CTLs from the PBMCs of HLA-A11+ and -A33+ patients.
Conclusion Therefore, the peptide at positions 30–39 of the core protein could be an appropriate target molecule of specific immunotherapy for all HLA-A11+, -A31+, and -A33+ patients with HCV1b-related diseases.
[validation ref - 4]
Opini Anda
Klik untuk menuliskan opini Anda tentang koleksi ini!
Lihat Sejarah Pengadaan
Konversi Metadata
Kembali
Process time: 0.15625 second(s)